Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
HeraMED Ltd. ( (AU:HMD) ) has shared an announcement.
HeraMED Limited announced that Broward Health will discontinue its use of the HeraCARE platform despite positive outcomes, due to changes in US healthcare policy affecting Medicaid funding. In response, HeraMED is refining its US market strategy by partnering with Aspire Health Innovations and appointing Jeff Garibaldi as Chief Growth Officer to accelerate growth and explore new opportunities, while also considering expansion into international markets with stable healthcare policies.
More about HeraMED Ltd.
HeraMED Limited is a medical data and technology company pioneering digital maternity care. The company focuses on improving maternal-fetal outcomes through innovative healthcare solutions, with a market focus on health systems serving diverse population segments in the US and other international markets.
YTD Price Performance: -5.00%
Average Trading Volume: 1,527,167
Technical Sentiment Signal: Sell
Current Market Cap: A$16.64M
For an in-depth examination of HMD stock, go to TipRanks’ Stock Analysis page.